Stock Yearly Return 2021
Start date: 01/04/2021
End date: 12/31/2021
Start price/share: $15.96
End price/share: $21.74
Dividends collected/share: $0.00
Total return: 36.22%
SRRA Average Annual Return: 36.62%
Starting investment: $10,000.00
Ending investment: $13,622.00
Years: 0.99


SRRA average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Compare SRRA average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Growth of $10,000.00
Without Dividends Reinvested Into SRRA


Also see:
SRRA YTD return
SRRA average annual return 10 years
Sierra Oncology is a late stage drug biopharmaceutical company on a quest to deliver targeted therapies that treat cancer. Co.'s main focus is the development of momelotinib, an investigational agent for the treatment of myelofibrosis. Momelotinib is an orally-bioavailable Janus kinase 1, Janus kinase 2 and Activin A receptor type 1 inhibitor with a mechanism of action, enabling it to potentially address all three hallmarks of disease in myelofibrosis: anemia of inflammation, constitutional symptoms and enlarged spleen. Co.'s portfolio also includes SRA737, a selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1, an emerging target for the treatment of cancer. The SRRA stock yearly return is shown above.

The yearly return on the SRRA stock yearly return page and across the coverage universe of our site, is a measure of the annual return over the calendar year 2021 for the given stock. When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is more than just the change in price if that instrument pays a dividend or coupon.

One way to factor dividends into the return is simply to count them as cash — we don't do that here. Instead, our website aims to empower investors by performing the SRRA annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree SRRA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Sierra Oncology (SRRA) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

SRRK Average Annual Return
SRTS Average Annual Return
SSKN Average Annual Return
STAA Average Annual Return
STAB Average Annual Return
STE Average Annual Return
STIM Average Annual Return
STOK Average Annual Return
STRO Average Annual Return
STRR Average Annual Return
More Healthcare companies »

 

SRRA Stock Yearly Return 2021 | www.AverageAnnualReturn.com | Copyright © 2021 - 2022, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.